Trending...
- Mark Schork Selected As 'Board Observer' By Philadelphia Bar Foundation
- Steve Everett Jr. Named President of L.T. Hampel Corporation
- Jaeigh Gallagher Records: Redefining Independent Music and Global Pop Culture
TORONTO and PHILADELPHIA, Sept. 21, 2023 ~ MolecuLight Inc., a leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, presented 6 Clinical Posters, a Presentation, and a Hands-On Workshop at the American Professional Wound Care Association's (APWCA) Wound Week™. The event was held from September 20 - 24, 2023 in Philadelphia, PA.
Dr. Thomas Serena, the Founder and Medical Director of The SerenaGroup®, commented on the importance of MolecuLight's point-of-care imaging of bacterial load as an essential tool for all wound care practitioners. He said that the evidence is irrefutable and that it is supported by the results of their 1,447 patient, multi-center study titled "Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging". The use of MolecuLight reduced antibiotic usage by 78%, showing that identifying and characterizing elevated bacterial loads in wounds can help clinicians make more informed decisions and provide the most appropriate treatment.
More on The PennZone
Anil Amlani, MolecuLight's CEO expressed his excitement about the significant additional clinical evidence being presented at Wound Week 2023 showing the impressive results derived from MolecuLight point-of-care devices. He said that these clinical insights span the wound care continuum including wound hygiene, wound bed preparation, antimicrobial stewardship, and patient engagement (through the incorporation of MolecuLight). In addition to these benefits, MolecuLight is helping combat racial inequity by being an imaging technology that elevates the detection of bacteria across all skin tones. Involving MolecuLight in patient care has improved wound healing outcomes as shown by results from a new 12-week randomized controlled trial.
The 6 clinical posters and presentation featuring the MolecuLight i:X at Wound Week 2023 were presented by Dr. Alisha Oropallo (Northwell Comprehensive Wound Healing Center), Dr. Charles Andersen (Vascular/Endovascular/Limb Preservation Surgery Service), and Dr. Thomas Serena (SerenaGroup Research Foundation). These posters included 12-week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates; Pseudomonas Scrub Down: Advances in Wound Imaging Objectively Confirm the Efficacy of Acetic Acid Against this Pathogen; Bacterial load imaging of chronic wound bacteria supports patient adherence, empowerment and may prevent negative outcomes; Strategies to improve equity in wound bacterial-infection assessments on skin of color; Multimodal imaging device for real-time bacterial load and thermal imaging: a study of synergy in clinical wound assessment workflow; Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging; Co-localization of High Bacterial Load with Regions of Pain in Venous Leg Ulcers: Imaging Informs Interventions and Validates Patient Self-Reported Pain.
More on The PennZone
The Hands-On Skills Workshop was held on Saturday September 23rd from 2:45 pm – 4:45 pm where attendees had an opportunity to experience first hand how to use MolecuLight i:X® and DX™ imaging devices for themselves. They were also available for demonstration at booth #40 located in Exhibit Hall throughout Wound Week 2023.
MolecuLight Inc.'s presence at APWCA's Wound Week™ provided attendees with valuable insights into how their point-of-care fluorescence imaging can be used to detect elevated bacterial loads within wounds which can help clinicians make more informed decisions when providing treatment options to their patients while also helping combat racial inequity through its ability to detect bacteria across all skin tones.
Dr. Thomas Serena, the Founder and Medical Director of The SerenaGroup®, commented on the importance of MolecuLight's point-of-care imaging of bacterial load as an essential tool for all wound care practitioners. He said that the evidence is irrefutable and that it is supported by the results of their 1,447 patient, multi-center study titled "Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging". The use of MolecuLight reduced antibiotic usage by 78%, showing that identifying and characterizing elevated bacterial loads in wounds can help clinicians make more informed decisions and provide the most appropriate treatment.
More on The PennZone
- Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring
- PromptBuilder.cc Launches AI Prompt Generator Optimized For ChatGPT, Gemini, Grok & Claude
- UK Financial Ltd Advances Compliance Strategy With January 30th CATEX Exchange Listing Of Maya Preferred PRA Preferred Class Regulated Security Token
- NOW OPEN - New Single Family Home Community in Manalapan
- Kintetsu And Oversee Announce New Partnership
Anil Amlani, MolecuLight's CEO expressed his excitement about the significant additional clinical evidence being presented at Wound Week 2023 showing the impressive results derived from MolecuLight point-of-care devices. He said that these clinical insights span the wound care continuum including wound hygiene, wound bed preparation, antimicrobial stewardship, and patient engagement (through the incorporation of MolecuLight). In addition to these benefits, MolecuLight is helping combat racial inequity by being an imaging technology that elevates the detection of bacteria across all skin tones. Involving MolecuLight in patient care has improved wound healing outcomes as shown by results from a new 12-week randomized controlled trial.
The 6 clinical posters and presentation featuring the MolecuLight i:X at Wound Week 2023 were presented by Dr. Alisha Oropallo (Northwell Comprehensive Wound Healing Center), Dr. Charles Andersen (Vascular/Endovascular/Limb Preservation Surgery Service), and Dr. Thomas Serena (SerenaGroup Research Foundation). These posters included 12-week RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates; Pseudomonas Scrub Down: Advances in Wound Imaging Objectively Confirm the Efficacy of Acetic Acid Against this Pathogen; Bacterial load imaging of chronic wound bacteria supports patient adherence, empowerment and may prevent negative outcomes; Strategies to improve equity in wound bacterial-infection assessments on skin of color; Multimodal imaging device for real-time bacterial load and thermal imaging: a study of synergy in clinical wound assessment workflow; Antimicrobial prescribing trends in 1,447 outpatient wound assessments: baseline rates and impact of bacterial fluorescence imaging; Co-localization of High Bacterial Load with Regions of Pain in Venous Leg Ulcers: Imaging Informs Interventions and Validates Patient Self-Reported Pain.
More on The PennZone
- Save 10 Percent Off KeysCaribbean's Newly Added Luxury Vacation Home in Marathon
- Why 'Instant-Liquidity' Gaming is Dominating the Nordic Tech Demographic
- STATEMENT: Shincheonji on Religious Freedom Controversy
- SheRising: Friends in Solidarity Hosts Webinar on Women in South Sudan
- Cyntexa Outlines a Principles-first Approach to Modern Enterprise Transformation
The Hands-On Skills Workshop was held on Saturday September 23rd from 2:45 pm – 4:45 pm where attendees had an opportunity to experience first hand how to use MolecuLight i:X® and DX™ imaging devices for themselves. They were also available for demonstration at booth #40 located in Exhibit Hall throughout Wound Week 2023.
MolecuLight Inc.'s presence at APWCA's Wound Week™ provided attendees with valuable insights into how their point-of-care fluorescence imaging can be used to detect elevated bacterial loads within wounds which can help clinicians make more informed decisions when providing treatment options to their patients while also helping combat racial inequity through its ability to detect bacteria across all skin tones.
Filed Under: Business
0 Comments
Latest on The PennZone
- Radarsign Redefines Crosswalk Safety with Launch of CrossCommand™ RRFB Crosswalk
- OpenSSL Corporation Opens 2026 Advisory Committees' Elections: Shape the Future!
- Steve Everett Jr. Named President of L.T. Hampel Corporation
- Acuvance Acquires ROI Healthcare Solutions, Building a Dedicated Healthcare ERP Practice
- Max Tucci Award-Winning Media Powerhouse Launches New Podcast —Executive Produced by Emmy-Winning Daytime Icons Suzanne Bass & Fran Brescia Coniglio
- MILBERT.ai Brings Real Time Session Defense to Google Workspace and Google Cloud
- Appliance Outlet Caps Off a Record-Setting 2025 Nationwide, Gears Up for Even Greater Growth in 2026
- Perry County Real Estate Agency Partners with Internet Marketing Company
- Philadelphia HVAC Companies Were Not Created Equal
- Home Prices Just Hit 5X Median Income — So Americans Are Buying Businesses Instead of Houses
- Briggs Auction's Jan. 30 online Fine Estates Auction features artworks by Hans Hoffman, Hans Coper, Lucie Rie, Loet Vanderveen
- Peak Exteriors LLC to Open First Office in East Berlin in 2026
- CCHR White Paper Urges Government Crackdown on Troubled Teen and For-Profit Psychiatric Facilities
- MoMojo Records signs Billy Thompson
- Still Searching for the Perfect Valentine's Gift? Lick Personal Oils Offers Romantic, Experience-Driven Alternatives to Traditional Presents
- Jaeigh Gallagher Records: Redefining Independent Music and Global Pop Culture
- Boston Industrial Solutions' BPA Certified BX Series Raises the Bar for Pad Printing Inks
- Boston Corporate Coach™ Sets Global Standard for Executive Chauffeur Services Across 680 Cities
- UK Financial Ltd Announces CoinMarketCap Supply Verification And Market Positioning Review For Regulated Security Tokens SMPRA And SMCAT
- Sharpe Automotive Redefines Local Car Care with "Transparency-First" Service Model in Santee